Table of Contents
When a patient is in hospital, they get chest X-rays and lung function tests. Most days, a medical professional listens to see if their breathing is improving.
But when a patient leaves the hospital, all that monitoring stops.
Early-warning signs of decline - like increases in wheezing or coughing spikes, can go unnoticed.
Strados Labs have built a wearable device that takes notice.
The RESP Biosensor is FDA-cleared, sits on the chest wall, and acts as a 24/7 stethoscope for your lungs:
- 93% sensitivity and 97% specificity for identifying coughs, wheezing and crackles
- Validated for 24+ hours of continuous recording, capturing a full day-night cycle of lung architecture
- Over 1.5 million lung sounds and 50 million breaths recorded, forming one of the world's largest clinical-grade bioacoustic datasets
The outcome: earlier detection of respiratory decline - before a patient even feels symptomatic - resulting in fewer admissions to hospital.
At JPM 2026, Onyx caught up with CEO Nick Delmonico to explore how every breath counts, and how he is scaling this life-saving technology.
A special thanks to our Onyx Live sponsors:
HUMPHREYS LAW - a focused, full-service law firm advising clients in the technology and media sectors. https://humphreys.law/
Panacea - AI-powered FDA consultants. File your IND in half the time. https://withpanacea.com/
Yours sincerely,
Dr. Adil Ali
Comments